Moderna, Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bullish +45

Moderna Plunges 20% One Day After Cancer Vaccine Breakthrough Sent Shares Up 177%

AI-generated analysis

📉 Moderna shares plunged 20% on Thursday after surging 177% on Wednesday following positive Phase 3 melanoma trial results.

💊 The mRNA-4157 vaccine combined with KEYTRUDA achieved a 49% reduction in recurrence or death versus KEYTRUDA alone in high-risk melanoma patients.

🔬 Moderna has nine Phase 2 and Phase 3 studies underway across melanoma, NSCLC, bladder cancer, and renal cell carcinoma.

💰 The company paid a $950 million litigation settlement in July 2026 while its norovirus program failed to meet statistical criteria at interim analysis.

📈 Moderna's one-week stock performance stands at 117.31% and year-to-date performance is up 369.03%.

🤝 The successful adjuvant melanoma combination extends Merck's KEYTRUDA franchise into earlier lines of therapy ahead of patent expiration.

👨‍💼 CEO Stéphane Bancel stated the company anticipates important pivotal readouts for intismeran in melanoma and propionic acidemia programs.

Bullish Signals
  • Moderna's mRNA cancer vaccine met key Phase 3 trial goals, delivering a 49% reduction in recurrence or death versus KEYTRUDA alone in advanced melanoma patients.
  • The company has nine studies underway across multiple cancer types including melanoma, NSCLC, bladder cancer, and renal cell carcinoma, validating its oncology platform.
  • A validated oncology franchise changes the company's story, potentially transforming it from a respiratory-vaccine business into a major oncology player.
Risk Factors
  • Shares crashed 20% on Thursday as investors took profits and reconsidered the immediate financial impact of the breakthrough after a 177% single-day rally.
  • The company carries pipeline overhangs including a $950 million litigation settlement paid in July 2026 and a norovirus program that failed to meet statistical criteria for early success.
Full Analysis
Moderna (MRNA) experienced extreme stock volatility following the release of Phase 3 trial data for its mRNA cancer vaccine candidate, intismeran autogene (mRNA-4157). The stock surged 177% on Wednesday after the combination therapy met key goals in a study of patients with advanced melanoma, showing a 49% reduction in recurrence or death compared to KEYTRUDA alone. However, shares subsequently crashed 20% by Thursday afternoon as investors took profits and recalibrated valuations following such a dramatic single-day move. The clinical data presented at ASCO 2026 validates Moderna's oncology franchise potential, with nine studies currently underway across melanoma, NSCLC, bladder cancer, and renal cell carcinoma. CEO Stéphane Bancel highlighted the importance of these pivotal readouts for both melanoma and propionic acidemia programs. The success of this personalized neoantigen therapy could transform Moderna from a respiratory-vaccine business into a major oncology player, significantly extending Merck's KEYTRUDA franchise utility. Despite the scientific breakthrough, the market reaction suggests investors are pricing in substantial commercial success before regulatory approval is secured. The company recently paid a $950 million litigation settlement and faced interim analysis failures in its norovirus program, creating pipeline overhangs that may have contributed to the profit-taking. Management maintains that the mRNA platform offers significant optionality, but the immediate stock correction reflects a reassessment of the magnitude of this potential new revenue stream.